Dr. Ian Flinn, chief scientific officer at Tennessee Oncology and One Oncology in Nashville, Tennessee, explains Lunsumio VELO (mosunetuzumab), a bispecific antibody,...
Joe McDonough, president of The Andrew McDonough B+ (Be Constructive) Basis, has spent practically 20 years supporting youngsters with most cancers and...
